<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04017572</url>
  </required_header>
  <id_info>
    <org_study_id>PCT171447</org_study_id>
    <nct_id>NCT04017572</nct_id>
  </id_info>
  <brief_title>Optimized vs. Standard Automated Peritoneal Dialysis Regimens Study</brief_title>
  <acronym>OptiStAR</acronym>
  <official_title>Optimized vs. Standard Automated Peritoneal Dialysis Regimens (OptiStAR): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carl M. Öberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de Córdoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is designed to evaluate the theoretical prediction of a lower glucose
      absorption in optimized automated peritoneal dialysis regimes. Patients will receive both a
      standard 6 x 2L 1.36% glucose regime or an optimized 7 x 2 L 2.27% glucose + 5 x 2 L 0.1%
      glucose regime in a crossover fashion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Automated peritoneal dialysis (APD) is a rapidly growing, home-based kidney replacement
      therapy promoting patient autonomy, and is associated with lower societal costs compared to
      hemodialysis. However, in light of the growing number of diabetic patients on PD, the
      unwanted glucose absorption during APD is problematic. Recent results (Öberg CM, Rippe B,
      2017, see references), using a theoretical model of APD, indicate that large reductions in
      glucose absorption are possible by using specialized so-called optimized bi-modal treatment
      regimes having &quot;UF cycles&quot; using a higher glucose concentration (e.g. 2.27% glucose) and
      &quot;Clearance cycles&quot; using a low glucose concentration (e.g. 0.1% glucose).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose absorption</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Amount of glucose absorbed across the peritoneal membrane during the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ultrafiltration</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Amount of water transported from the circulation to the peritoneal cavity during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine clearance</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Amount of creatinine transported from the circulation to the peritoneal cavity during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urea clearance</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Amount of urea transported from the circulation to the peritoneal cavity during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium removal</measure>
    <time_frame>Through study completion, up to 1 year</time_frame>
    <description>Amount of sodium transported from the circulation to the peritoneal cavity during the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications</measure>
    <time_frame>Up to 14 days post-intervention</time_frame>
    <description>Complications that are or can be suspected to be related to the study intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>End Stage Kidney Disease</condition>
  <condition>Chronic Kidney Disease Requiring Chronic Dialysis</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>APD-treatment with a net volume of 12 L 1.36 % anhydrous glucose peritoneal dialysis solution during 540 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimized treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>APD-treatment with a net volume of 14 L 2.27 % anhydrous glucose peritoneal dialysis solution during 280 minutes followed by a net volume of 10 L 0.1 % glucose dialysis fluid during 200 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Automated peritoneal dialysis (APD)</intervention_name>
    <description>Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.</description>
    <arm_group_label>Optimized treatment</arm_group_label>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 75 years;

          -  duration of PD (automated peritoneal dialysis (APD) or continuous ambulatory
             peritoneal dialysis (CAPD)) &gt;4 weeks

        Exclusion Criteria:

          -  severe heart failure (New York Heart Association Functional Classification; NYHA III
             or IV);

          -  pregnancy;

          -  catheter malfunction or

          -  peritonitis within 3 months prior to the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl M Öberg, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carl M Öberg, M.D., Ph.D.</last_name>
    <phone>+46-709-221947</phone>
    <email>Carl.Oberg@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Javier de Arteaga, M.D., Ph.D.</last_name>
    <phone>+54-351-4688230</phone>
    <email>javierdearteaga@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Privado Centro Médico de Córdoba</name>
      <address>
        <city>Córdoba</city>
        <zip>5016</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier de Arteaga, M.D., Ph.D.</last_name>
      <phone>+54 351 4688230</phone>
      <email>javierdearteaga@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Javier de Arteaga, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl M Öberg, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <reference>
    <citation>Öberg CM, Rippe B. Optimizing Automated Peritoneal Dialysis Using an Extended 3-Pore Model. Kidney Int Rep. 2017 Apr 27;2(5):943-951. doi: 10.1016/j.ekir.2017.04.010. eCollection 2017 Sep.</citation>
    <PMID>29270500</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Carl M. Öberg</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>dialysis</keyword>
  <keyword>peritoneal dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

